
About Afrezza
Afrezza is a Healthcare company based in United States founded in 2009. It provides rapid-acting inhaled insulin for blood sugar control in diabetes patients. It operates on a B2C model. Afrezza offers products and services including Afrezza. Its focus areas include Biotechnology, Drug Delivery, Inhaled Medications and Pharmaceuticals. Its legal entity is MannKind Corporation. Its competitors include MannKind Corp, Impel NeuroPharma and Alexza; 3 of its 3 listed competitors have raised funding.
Company details
MannKind Corporation manufactures Afrezza, a rapid-acting inhaled insulin that lowers blood sugar in about 12 minutes for adults with type 1 or type 2 diabetes. It operates through online consultations and resources, targeting US residents, and offers support like savings cards and FAQs. The company focuses on needle-free delivery and collaborates with healthcare providers for accessibility.
- Headquarters United States
- SectorsHealthcare
- Phone•••• ••••
- Website afrezza.com
- Social Facebook Instagram YouTube
- Legal Name Mannkind Corporation
Products & Services of Afrezza
Afrezza offers a comprehensive portfolio of products and services, including Afrezza.
Rapid-acting insulin for controlling blood sugar in diabetes patients.
Apps and channels of Afrezza
its YouTube channel AFREZZA has 834 subscribers and 10 videos.
Videos from Afrezza
The most watched videos on Afrezza's YouTube channel, AFREZZA (834 subscribers). Click a video to play it here.
More on AFREZZA.
Competitors of Afrezza
Afrezza has 3 listed competitors in our database, 3 of them funded. They include MannKind Corp, Impel NeuroPharma and Alexza.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| mannkindcorp.com | 1991 | Los Angeles, United States | $50M | 322 | Developer of small-molecule drugs | |
| impelnp.com | 2008 | Seattle, United States | $126.83M | 158 | Intranasal delivery technology for CNS diseases is developed. | |
| alexza.com | 2000 | Mountain View, United States | $97M | 72 | Developer of products for the treatment of acute and intermittent conditions |
Detailed competitors of Afrezza
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Afrezza
Websites that share an audience with Afrezza (afrezza.com).
Websites whose visitors overlap most with Afrezza. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| myceqursimplicity.com | 100% | 59.5K | View details | ||
| eaglepharmacy.com | 100% | 37.2K | #566,679 | View details |
Top companies in Biopharma Outsourcing & Drug Delivery
3 companies that operate in the same segment as Afrezza (Biopharma Outsourcing & Drug Delivery) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Suite solutions are provided for payers and healthcare providers. | 1998 | Princeton, New Jersey, United States | USD 220 M | USD 374.1 M | 5,666 | |
Wearable insulin infusion systems are developed for diabetes patients. | 2000 | Boston, Massachusetts, United States | USD 120.4 M | USD 2.71 B | 3,900 | |
Developer of small-molecule drugs | 1991 | Los Angeles, California, United States | USD 50 M | USD 348.97 M | 407 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Afrezza
Complete news archive for Afrezza
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Afrezza
Afrezza was founded in 2009.
Afrezza is headquartered in United States.
MannKind Corporation manufactures Afrezza, a rapid-acting inhaled insulin that lowers blood sugar in about 12 minutes for adults with type 1 or type 2 diabetes. It operates through online consultations and resources, targeting US residents, and offers support like savings cards and FAQs. The company focuses on needle-free delivery and collaborates with healthcare providers for accessibility.
Afrezza's top competitors include MannKind Corp, Impel NeuroPharma and Alexza.
Afrezza offers Afrezza.
Afrezza operates through Mannkind Corporation.
